Avidity Biosciences (RNA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Avidity Biosciences (RNA)
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Key Insights
Critical company metrics and information
Share Price
$37.93Market Cap
$4.53 BillionTotal Outstanding Shares
119.31 Million SharesTotal Employees
253Dividend
No dividendIPO Date
June 12, 2020SIC Description
Pharmaceutical PreparationsHomepage
https://www.aviditybiosciences.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $1.21 Billion |
| Net Cash Flow From Financing Activities, Continuing | $1.21 Billion |
| Net Cash Flow, Continuing | $287.04 Million |
| Net Cash Flow From Investing Activities, Continuing | $-738.99 Million |
| Net Cash Flow From Operating Activities | $-184.50 Million |
| Net Cash Flow From Investing Activities | $-738.99 Million |
| Net Cash Flow From Operating Activities, Continuing | $-184.50 Million |
| Net Cash Flow | $287.04 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Nonoperating Income/Loss | $44.20 Million |
| Revenues | $10.12 Million |
| Operating Expenses | $334.81 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Income/Loss From Continuing Operations After Tax | $-280.49 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Net Income/Loss Attributable To Parent | $-280.49 Million |
| Research and Development | $260.79 Million |
| Income/Loss From Continuing Operations Before Tax | $-197.75 Million |
| Operating Income/Loss | $-324.69 Million |
| Benefits Costs and Expenses | $290.61 Million |
| Basic Average Shares | $318.54 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-280.49 Million |
| Costs And Expenses | $290.61 Million |
| Diluted Average Shares | $318.54 Million |
| Other Operating Expenses | $74.02 Million |
| Diluted Earnings Per Share | $2.89 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Basic Earnings Per Share | $2.89 |
| Net Income/Loss | $-280.49 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $1.64 Billion |
| Other Non-current Assets | $9.41 Million |
| Fixed Assets | $9.49 Million |
| Other Current Assets | $7.80 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Cash | $1.60 Billion |
| Equity Attributable To Parent | $1.50 Billion |
| Noncurrent Liabilities | $46.06 Million |
| Other Current Liabilities | $83.67 Million |
| Liabilities | $137.39 Million |
| Assets | $1.64 Billion |
| Current Liabilities | $91.33 Million |
| Accounts Payable | $7.66 Million |
| Equity | $1.50 Billion |
| Current Assets | $1.62 Billion |
| Prepaid Expenses | $14.06 Million |
| Noncurrent Assets | $18.91 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.